NUTEX HEALTH PROVIDES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS, ANNOUNCES DELAY IN FILING ITS 2025 SECOND QUARTER FINANCIAL STATEMENTS AND ANNOUNCES A STOCK REPURCHASE PROGRAM OF UP TO $25 MILLION
Nutex Health (NASDAQ: NUTX), a physician-led healthcare system with 24 micro hospitals across 11 states, announced three significant updates: preliminary Q2 2025 results, a Form 10-Q filing delay, and a $25 million stock repurchase program.
The company reported strong Q2 2025 performance with revenue of $244.0 million, up 220.7% year-over-year, and gross profit of $124.9 million (51.2% margin). Total hospital visits increased by 10.6% to 45,573. For H1 2025, revenue reached $455.8 million, up 217.5%, with gross profit of $243.3 million.
The Form 10-Q filing delay is due to non-cash accounting adjustments related to stock-based compensation for under-construction hospitals. The company expects to file within the five-day grace period and confirms these adjustments won't affect revenue, gross profit, or operations.
Nutex Health (NASDAQ: NUTX), un sistema sanitario guidato da medici con 24 micro-ospedali in 11 stati, ha annunciato tre aggiornamenti importanti: risultati preliminari del 2° trimestre 2025, il rinvio della presentazione del Modulo 10-Q e un programma di riacquisto di azioni da 25 milioni di dollari.
L'azienda ha registrato un solido 2° trimestre 2025 con ricavi per 244,0 milioni di dollari, in aumento del 220,7% rispetto all'anno precedente, e un utile lordo di 124,9 milioni di dollari (margine del 51,2%). Le visite totali in ospedale sono aumentate del 10,6% a 45.573. Per il primo semestre 2025, i ricavi hanno raggiunto 455,8 milioni di dollari, in crescita del 217,5%, con un utile lordo di 243,3 milioni di dollari.
Il rinvio della presentazione del Modulo 10-Q è dovuto ad aggiustamenti contabili non monetari relativi alla remunerazione azionaria per ospedali in costruzione. La società prevede di presentare entro il periodo di grazia di cinque giorni e conferma che tali aggiustamenti non influiranno su ricavi, utile lordo o operazioni.
Nutex Health (NASDAQ: NUTX), un sistema de salud dirigido por médicos con 24 microhospitales en 11 estados, anunció tres novedades importantes: resultados preliminares del 2T 2025, el aplazamiento de la presentación del Formulario 10-Q y un programa de recompra de acciones de 25 millones de dólares.
La compañÃa informó un sólido 2T 2025 con ingresos de 244,0 millones de dólares, un aumento interanual del 220,7%, y beneficio bruto de 124,9 millones de dólares (margen del 51,2%). Las visitas hospitalarias totales aumentaron un 10,6% hasta 45.573. En el 1S 2025, los ingresos alcanzaron 455,8 millones de dólares, un 217,5% más, con un beneficio bruto de 243,3 millones de dólares.
El retraso en la presentación del Formulario 10-Q se debe a ajustes contables no monetarios relacionados con la compensación basada en acciones para hospitales en construcción. La compañÃa espera presentar dentro del perÃodo de gracia de cinco dÃas y confirma que dichos ajustes no afectarán a los ingresos, el beneficio bruto ni las operaciones.
Nutex Health (NASDAQ: NUTX), 11ê°� ì£¼ì— 24ê°� 마ì´í¬ë¡œ 병ì›ì� ìš´ì˜í•˜ëŠ” ì˜ì‚¬ 주ë„ì� ì˜ë£Œ ì‹œìŠ¤í…œì´ ì„� 가지 주요 소ì‹ì� 발표했습니다: 2025ë…� 2분기 ìž ì • 실ì , Form 10-Q ì œì¶œ ì§€ì—�, 그리ê³� 2,500ë§� 달러 규모ì� ìžì‚¬ì£� 매입 프로그램입니ë‹�.
회사ëŠ� 2025ë…� 2분기ì—� 매출 2ì–� 4,400ë§� 달러ë¡� ì „ë…„ 대ë¹� 220.7% ì¦ê°€í–ˆê³ , ì´ì´ì� 1ì–� 2,490ë§� 달러(마진 51.2%)ë¥� 기ë¡í•˜ë©° 강한 실ì ì� ë³´ì˜€ë‹¤ê³ ë³´ê³ í–ˆìŠµë‹ˆë‹¤. ë³‘ì› ì´� 방문 수는 10.6% ì¦ê°€í•� 45,573ê±´ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 2025ë…� ìƒë°˜ê¸� ë§¤ì¶œì€ 4ì–� 5,580ë§� 달러ë¡� 217.5% ì¦ê°€í–ˆìœ¼ë©�, ì´ì´ìµì€ 2ì–� 4,330ë§� 달러였습니ë‹�.
Form 10-Q ì œì¶œ ì§€ì—°ì€ ê±´ì„¤ ì¤‘ì¸ ë³‘ì›ì—� 대í•� ì£¼ì‹ ê¸°ë°˜ ë³´ìƒê³� ê´€ë ¨ëœ ë¹„í˜„ê¸ˆì„± 회계 ì¡°ì • 때문입니ë‹�. 회사ëŠ� 5ì� ìœ ì˜ˆ 기간 ë‚� ì œì¶œí•� ì˜ˆì •ì´ë©°, ì´ëŸ¬í•� ì¡°ì •ì� 매출, ì´ì´ì� ë˜ëŠ” ìš´ì˜ì—� ì˜í–¥ì� 미치지 ì•Šì„ ê²ƒì´ë¼ê³ 확ì¸í–ˆìŠµë‹ˆë‹¤.
Nutex Health (NASDAQ: NUTX), un système de santé dirigé par des médecins avec 24 micro-hôpitaux dans 11 États, a annoncé trois informations importantes : les résultats préliminaires du T2 2025, le report du dépôt du formulaire 10-Q et un programme de rachat d’actions de 25 millions de dollars.
La société a déclaré une solide performance au T2 2025 avec un chiffre d’affaires de 244,0 millions de dollars, en hausse de 220,7 % sur un an, et un bénéfice brut de 124,9 millions de dollars (marge de 51,2 %). Le nombre total de visites hospitalières a augmenté de 10,6 % pour atteindre 45 573. Sur le 1er semestre 2025, le chiffre d’affaires s’est élevé à 455,8 millions de dollars, en hausse de 217,5 %, avec un bénéfice brut de 243,3 millions de dollars.
Le retard de dépôt du formulaire 10-Q est dû à des ajustements comptables non monétaires liés à la rémunération en actions pour les hôpitaux en construction. La société prévoit de déposer dans le délai de grâce de cinq jours et confirme que ces ajustements n’affecteront pas le chiffre d’affaires, le bénéfice brut ni les opérations.
Nutex Health (NASDAQ: NUTX), ein von Ärzten geführtes Gesundheitssystem mit 24 Mikrokliniken in 11 Bundesstaaten, hat drei wichtige Neuigkeiten bekanntgegeben: vorläufige Ergebnisse für Q2 2025, eine Verzögerung bei der Einreichung des Formulars 10-Q und ein Aktienrückkaufprogramm in Höhe von 25 Millionen US-Dollar.
Das Unternehmen meldete eine starke Performance im Q2 2025 mit Umsatz von 244,0 Mio. USD, ein Plus von 220,7% gegenüber dem Vorjahr, und einem Bruttogewinn von 124,9 Mio. USD (Marche 51,2%). Die Gesamtanzahl der Krankenhausbesuche stieg um 10,6% auf 45.573. Für H1 2025 erreichten die Umsätze 455,8 Mio. USD, ein Anstieg von 217,5%, mit einem Bruttogewinn von 243,3 Mio. USD.
Die Verzögerung bei der Einreichung des Formulars 10-Q ist auf nicht zahlungswirksame buchhalterische Anpassungen im Zusammenhang mit aktienbasierter Vergütung für sich im Bau befindliche Krankenhäuser zurückzuführen. Das Unternehmen erwartet die Einreichung innerhalb der fünf Tage Schonfrist und bestätigt, dass diese Anpassungen Umsatz, Bruttogewinn oder den Betrieb nicht beeinflussen werden.
- Revenue surged by 220.7% YoY to $244.0 million in Q2 2025
- Gross profit margin improved significantly to 51.2% from 29.7% YoY
- Hospital visits increased 10.6% to 45,573 in Q2 2025
- Strong cash position of $96.6 million as of June 30, 2025
- $25 million stock repurchase program announced to enhance shareholder value
- Delay in filing Q2 2025 Form 10-Q due to accounting adjustments
- Cancellation of scheduled earnings conference call
- Financial results are preliminary and subject to adjustments
Insights
Nutex reports massive 220% revenue growth with delayed 10-Q filing and announces $25M share repurchase program to enhance shareholder value.
Nutex Health's preliminary Q2 2025 results reveal extraordinary financial performance with revenue surging
The company's robust balance sheet shows
The delayed 10-Q filing warrants attention but appears contained to non-cash accounting adjustments related to stock-based compensation for under-construction and ramping hospitals. Importantly, management states these adjustments won't impact revenue, gross profit, liquidity, or working capital metrics.
The newly announced
The half-year results mirror the quarterly performance with revenue up
The Company expects that any non-cash adjustments related to the treatment of these obligations will have no effect on its revenue, gross profit, liquidity, working capital or number of patient visits.
The Company is working diligently with its auditors to address the matter in a timely and efficient manner. As disclosed in its Form 12b-25, the Company expects to file the Form 10-Q for the period ended June 30, 2025 within the SEC-prescribed five calendar day grace period.
The Company provided select preliminary unaudited financial results for the three and six months ended June 30, 2025. The preliminary financial information presented below reflects management's current views with respect to the Company's financial results. These preliminary results remain subject to the completion of normal quarter-end and fiscal-end accounting procedures and closing adjustments. Nutex Health will release its full financial results as promptly as reasonably practicable.
The Company hereby announces the cancellation of the conference call that was originally scheduled Friday, August 15, 2025, at 10:30 a.m. ET. The Company will reschedule the conference call as soon as possible where it will discuss 2nd Quarter financials as well as other topics relevant to the Company.
Financial highlights for the three months ended June 30, 2025:
- Total revenue was
for the three months ended June 30, 2025 as compared to total revenue of$244.0 million for the same period in 2024, an increase of$76.1 million 220.7% . Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by203.2% in 2025 compared to 2024. - Gross profit was
, or$124.9 million 51.2% of total revenue, for the three months ended June 30, 2025 as compared to gross profit of , or$22.6 million 29.7% of total revenue, for the same period in 2024. - Total visits at the Hospital Division were 45,573 for the three months ended June 30, 2025, as compared to 41,208 for the same period in 2024, an increase of 4,365 or
10.6% . Visits at mature hospitals increased by0.6% in the three months ended June 30, 2025 as compared to the same period in 2024. - As of June 30, 2025, the Company had total assets of
, including cash of$855.1 million .$96.6 million
Financial highlights for the six months ended June 30, 2025:
- Total revenue was
for the six months ended June 30, 2025, as compared to total revenue of$455.8 million for the same period in 2024, an increase of$143.5 million 217.5% . Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by195.2% in 2025 compared to 2024. - Gross profit was
, or$243.3 million 53.4% of total revenue, for the six months ended June 30, 2025, as compared to gross profit of , or$32.7 million 22.8% of total revenue, for the same period in 2024. - Total visits at the Hospital Division were 93,842 for the six months ended June 30, 2025, as compared to 81,276 for the same period in 2024, an increase of 12,566 or
15.5% . Visits at mature hospitals increased by3.0% in the six months ended June 30, 2025, as compared to the same period in 2024.
Share Repurchase Program
The Board of Directors has authorized a stock repurchase program of up to
The timing of any repurchases and the number of shares repurchased are subject to the discretion of the Company and may be affected by various factors, including general market and economic conditions, the market price of the Company's common stock, the Company's earnings, financial condition, capital requirements and levels of indebtedness, legal requirements, and other factors that management may deem relevant. The share repurchase program authorization does not obligate the Company to acquire any shares of its common stock and may be amended, suspended or discontinued at any time.
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 24 facilities in 11Â states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
- This Press Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, changes in laws or regulations applicable to our operations, in particular, changes to the regulations promulgated under the No Surprises Act, any statements about our business, financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, or otherwise, and our future liquidity, including cash flows; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; or strategic transactions; any statements regarding management's view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "think," "plan," "envision," "intend," "continue," "target," "seek," "contemplate," "budgeted," "will," "would" and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology.
ÌýÌý - Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading "Item 1A. Risk Factors" included in the Annual Report of Nutex Health Inc. on Form 10-K for the year ended December 31, 2024 and other filings of the Company with the United States Securities and Exchange Commission. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.
View original content:
SOURCE Nutex Health, Inc.